Sandra SIGALA

Associate Professor of Pharmacology

University of Brescia

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Cancer Biology Cancer Biology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Sandra Sigala is an Associate Professor of Pharmacology at the University of Brescia, Italy. Her research primarily focuses on the therapeutic potential of targeting specific kinases in adrenocortical carcinomas, as well as the investigation of steroidogenic signaling and the efficacy of various pharmacological treatments for cancer. Her recent publications include studies on the use of CDK inhibitors and the role of progesterone in cancer cell lines.

Articles (13)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (6)

Constanze Hantel

University Hospital of Zurich

SWITZERLAND

View details

Dario Finazzi

Associate Professor

University of Brescia

ITALY

View details

David Penton

University of Zurich

SWITZERLAND

View details

Alfredo Berruti

University of Brescia

ITALY

View details

Elisa Rossini

Collaboratore Professionale di Ricerca Sanitaria

Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna "Bruno Ubertini"

ITALY

View details

Marco Presta

University of Brescia

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sandra SIGALA

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Therapeutic potential of targeting the FLNA‐regulated Wee1 kinase in adrenocortical carcinomas

The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study

Human and Murine Cell Lines for Adrenocortical Carcinoma and Pheochromocytoma

Correction: Sigala et al. A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma. Cells 2022, 11, 1439

Feasibility and Activity of Megestrol Acetate in Addition to Etoposide, Doxorubicin, Cisplatin, and Mitotane as First-Line Therapy in Patients with Metastatic/Unresectable Adrenocortical Carcinoma with Low Performance Status

Preclinical Evidence of Progesterone as a New Pharmacological Strategy in Human Adrenocortical Carcinoma Cell Lines

A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma

Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor-α

Caffeine Inhibits Direct and Indirect Angiogenesis in Zebrafish Embryos

Adrenocortical Carcinoma

The long and winding road to effective immunotherapy in patients with adrenocortical carcinoma

Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria

Hyperthermic Intraperitoneal Chemotherapy for Primary or Recurrent Adrenocortical Carcinoma. A Single Center Study

Collaborators (6)

Constanze Hantel

Dario Finazzi

David Penton

Alfredo Berruti

Elisa Rossini

Marco Presta

Make your next move.